Supplier News: WuXi STA, Delpharm, Asymchem & More
By

The latest from CDMOs, CMOs, and suppliers featuring WuXi STA, Delpharm. Asymchem, Abzena, Scorpion Biological Services, Formulated Solutions, and Polysciences.

Chemicals/Chemical API Manufacturing 
* Asymchem Opens R&D Site   
Biologics Manufacturing 
* BMS Completes Mfg Facility Sale to Lotte Biologics
* Abzena Appoints New CEO 
* Scorpion Biological Rebrands as Scorpius BioManufacturing 
* Polysciences Launches Bioprocessing Brand Kyfora Bio 
Formulation Development/Drug Product Manufacturing 
* WuXi STA Opens Continuous Mfg Line for Oral Solids 
* Delpharm Acquires Injectable Drug Mfg Facility 
* Formulated Solutions To Acquire Drug-Product Mfg Facility


Chemicals/Chemical API Manufacturing 

Asymchem Opens Early-Stage R&D Site 
Asymchem Laboratories, a Tianjin, China-based CDMO of small-molecule active pharmaceutical ingredients (APIs), intermediates and drug products, has opened new site for early-stage R&D services, including chemical process development, pre-formulation study and formulation development for small molecules, peptides, and oligonucleotides in Woburn, Massachusetts. The site is part of Asymchem Boston, a wholly owned subsidiary of Asymchem Group.  

After establishing the location in August 2022, the site is now ready for full operation. It has 6,000 square feet of existing lab space that includes process and analytical labs and space to expand an additional 4,500 square feet. Solid characterization and pre-formulation labs will be ready in the first quarter of 2023. By the third quarter of 2023, continued expansion will include a fully functional kilo lab, formulation R&D, and an oligonucleotide and peptide lab to support drug-substance and drug-product development and non-GMP production. 

Source: Asymchem 


Biologics Manufacturing 

BMS Completes Mfg Facility Sale to Lotte Biologics 
Bristol Myers Squibb (BMS) has completed the sale of its biomanufacturing facility in Syracuse, New York to Lotte Biologics, a Lotte Corporation company, and new established CDMO. Lotte Corporation is a Seoul, Korea-based holding company of Lotte Group with holdings in chemicals, food & beverage, retail, and hotel & services. 

As part of the transaction, Lotte has offered all employees at the site employment within its business. Lotte acquired the Syracuse site’s operations and assets, which includes the property, plant and equipment. BMS formed a newly established CMO relationship with Lotte, under which Lotte will manufacture product for BMS at the Syracuse facility. 

Source: Bristol Myers Squibb 


Abzena Appoints New CEO 
Abzena, a San Diego, California-based CDMO of biologics and antibody drug conjugates, has appointed Matthew Stober, formerly CEO of CastleVax, a New York City-based vaccine company, and Istari Oncology, a Morrisville, North Carolina-based bio/pharmaceutical company, as its new CEO. 

Earlier in his career, Stober held executive positions at Merck & Co., GlaxoSmithKline, Novartis, and helped lead the operational turnaround of Hospira, resulting in the eventual sale of Hospira to Pfizer for $17 billion. 

Source: Abzena 


Scorpion Biological Rebrands as Scorpius BioManufacturing 
Scorpion Biological Services, a San Antonio, Texas-based CDMO of biologics, has changed its name to Scorpius BioManufacturing, reflecting the company’s recently expanded manufacturing capabilities and the opening of its new biomanufacturing facility in San Antonio in October (October 2022).  

The new facility offers GCP, GLP and GMP biomanufacturing capabilities in both mammalian and microbial modalities. Suites and equipment trains are flexible, with bioreactor sizes ranging from 50 L up to 2,000 L, Scorpius provides services to manufacture a wide range of products, including cell therapies, recombinant proteins from mammalian or microbial systems, and DNA vectors. 

Source: Scorpius BioManufacturing 


Polysciences Launches Bioprocessing Brand Kyfora Bio 
Polysciences, a Pennsylvania-based manufacturer of specialty chemicals for research, in vitro diagnostics, and medical device applications, has launched a new brand, Kyfora Bio, representing its product offerings to the bioprocessing market. 

Kyfora Bio will be based in Horsham, Pennsylvania, and will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies. It will occupy a 45,000-square-foot cGMP facility outfitted with administrative offices, R&D laboratories, manufacturing suites, and quality control laboratories for chemical and biological performance testing. 

Source: Kyfora Bio 


Formulation Development/Drug Product Manufacturing 

WuXi STA Opens Continuous Mfg Line for Oral Solids 
WuXi STA, a Wuxi, China-based CDMO of active pharmaceutical ingredients (APIs) and drug products and a subsidiary of WuXi AppTec, has begun operation of its first drug-product continuous manufacturing line for oral solids at its drug product site in Wuxi City, China.  

WuXi STA’s continuous manufacturing line features continuous direct compression equipment with unit operations, including dispensing, blending, lubrication, tablet compression, and coating.  

Source: WuXi STA 


Delpharm Acquires Injectable Drug Mfg Facility 
Delpharm, a Boulogne-Billancourt, France-based CDMO of drug products, has acquired an injectable drug-development facility in Leiden, the Netherlands from Dr Reddy’s Laboratories. This facility employs 40 personnel and is in a 3,500-square-meter unit, equipped with technologies to develop injectable formulations for small and large molecules and to manufacture small batches for clinical trials. 

With the acquisition of the Leiden site, Delpharm is now positioned as a complete player in injectables, from formulation, analytical development, Phase I clinical batches manufacturing, to production in one of the company’s four injectable plants (three in France and one in Canada). 

Source: Delpharm 


Formulated Solutions To Acquire Drug-Product Mfg Facility 
Formulated Solutions, a Largo, Florida-based CDMO of drug products for consumer healthcare products, has agreed to acquire a 455,000-square-foot production facility in Cleveland, Tennessee, for liquids, semisolids, aerosols, bag-on-valve products, and metered-dose nasal sprays production facility.  

The facility has capabilities for blending of liquids, semisolids, and suspensions and packaging capabilities for flexible tubes, liquid-fill bottles, and metered-dose sprays to traditional aerosol and bag-on-valve aerosol delivery systems that can support a large variety of development and commercial supply programs. 

Source: Formulated Solutions